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DEAR EDITOR, fatigue is a common symptom in patients with axial spondyloarthritis (axSpA), having been descri‐
bed by 67.2% of patients with AS, and a similar rate in non-radiographic axial spondyloarthritis (nr-axSpA, 68.2%)
[1].
Fatigue impacts upon quality of life [2], work productivity [3] and is associated with anxiety and depression [4].
We evaluated a broad selection of serum biomarkers (Supplementary Fig. S1, available at Rheumatology online),
in a large cross-sectional mixed cohort of axSpA patients. The objective was to identify biomarker signals related to
patient reported fatigue, defined by responses to Question 1 of the BASDAI [5], and explore the relationship with
disease activity.
The Bath Spondyloarthritis Biobank (Research Ethics Council reference 13/SW/0096) at the Royal National Hos‐
pital for Rheumatic Diseases (Bath) is a longitudinal database of patients over the age of 18 years, being referred with
a suspected or confirmed diagnosis of axSpA, following written patient consent. At the time of this study, the Bio‐
bank comprised 1176 patients with confirmed diagnoses, 77% with AS. The study was conducted in line with the
principles of the declaration of Helsinki.
Demographic and clinical information, patient-reported outcome measures (BASDAI, BASFI, patient global and
pain visual analogue scales) and BASMI are collected during routine clinical visits. Questionnaire and metrology data
completed closest to the date of biobank enrolment was used for analysis.
Patients included in the study were drawn from the database based upon the completeness of their data (clinical
data and serology) and had a confirmed diagnosis of AS (modified New York criteria), nr-axSpA (ASAS[AQ1] crite‐
ria) or mechanical back pain (MBP). A single 50 ml blood sample (serum and DNA) was collected at the time of
enrolment into the Biobank, and all samples were analysed centrally by Myriad RBM (Austin, TX, USA) using the
47-protein Lumina Panel (Human Inflammation Multi Analyte Profile v 1.0 multiplex and Ultra-High Sensitive
MCP-1 ELISA assays).
For each biomarker, lowest limit of quantitation (LLOQ, lowest amount of an analyte quantitatively determined
with acceptable precision, where the coefficient of variation after serial dilutions is 30%) and serum low to high range
(based upon 95% of the sample results from 100 healthy individuals) were reported.
Descriptive statistics were applied, using IBM SPSS Statistics version 24.0. All data were tested for normality us‐
ing the Shapiro–Wilks test and QQ plots. Where biomarker results were below the LLOQ, these were recoded as 0.
Data were described using means (s.d.) or median (interquartile range) as suitable. Where appropriate, Pearson Chi-
squared, Mann–Whitney U or Kruskal–Wallis tests were employed to evaluate distributions between independent
samples, and Spearman rank correlation coefficients were used to assess associations between non-parametric contin‐
uous independent samples.
Characteristics of the 273 patients are shown in Table 1: 195 (71.4%) were AS, 27 (9.9%) nr-axSpA and 51
(18.6%) MBP. A total of 88.8% of the AS cohort were HLA-B27 [AQ5]positive, compared with 77.8% in the nr-
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axSpA cohort and only 13.7% of MBP. AS patients were older (mean age 53.8 years, vs 34.0 and 29.9 years in the nr-
axSpA and MBP, P < 0.01), and had a higher proportion of males (74.4%, vs 44.4 and 43.1%, respectively, P < 0.01).
Fifty-eight (29.7%) AS patients and only one nr-axSpA were currently on anti-TNF medications. Mean (s.d.) disease
duration for AS was 22.5 years (13.6) and 1.8 years (4.2) in non-radiographic patients (P < 0.01).
Table 1 Cohort characteristics of patients evaluated for fatigue and serum biomarkers by diagnostic group
Characteristic AS nr-axSpA MBP P-value
n (%) 195 (71.4) 27 (9.9) 51 (18.6) —
Age, mean (s.d.), years 53.8 (13.4) 34.0 (9.0) 29.9 (9.4) <0.01
HLA-B27 positive 173 (88.7) 21 (77.8) 7 (13.7) <0.01
Male 145 (74.4) 12 (44.4) 22 (43.1) <0.01
Family history of SpA 50 (25.6) 10 (37.0) 7 (13.7) <0.01
Current smokers 40 (20.5) 5 (18.5) 12 (23.5) 0.08
Previous extraarticular manifestations 129 (66.2) 17 (63.0) 15 (29.4) <0.01
Current biologic therapy 58 (29.7) 1 (3.7) — <0.01
Disease duration, mean (s.d.), years 22.5 (13.6) 1.8 (4.2) 0.0 (0.1) <0.01
Total BASDAI, mean (s.d.) 3.8 (2.1) 4.8 (2.0) 5.3 (1.9) <0.01
BASDAI Q1, mean (s.d.) 4.7 (2.4) 5.2 (2.5) 5.5 (2.5) 0.08
Total BASDAI without Q1, mean (s.d.) 2.8 (1.7) 3.8 (1.7) 4.2 (1.7) <0.01
ASDAS, mean (s.d.) 2.7 (1.2) 2.4 (0.8) 2.7 (0.8) 0.41
BASFI, mean (s.d.) 4.0 (2.4) 2.6 (2.1) 3.6 (2.4) <0.01
BASMI, mean (s.d.) 4.1 (2.0) 1.6 (1.4) — <0.01
Number of patients with characteristic, n and percentage of group, %, unless stated. P-value using Kruskal–Wallis or
ANOVA as appropriate. nr-axSpA: non-radiographic axial spondyloarthritis.
Mean (s.d.) BASDAI Q1 score (which pertains specifically to fatigue) was highest in MBP [5.5 (2.5); nr-axSpA
5.2 (2.5), AS 4.7 (2.4), P = 0.08] but not significant.
Using Spearman rank, significant correlations (P ≤ 0.01) were found in patients with AS and nr-axSpA between
self-reported levels of fatigue (Q1) and their total BASDAI, BASDAI calculated excluding Q1, ASDAS, BASFI and
back pain scores.
Significant correlations (P ≤ 0.01) in the AS cohort were also found between fatigue and levels of serum biomark‐
ers macrophage inflammatory protein 1β (MIP1β) and VEGF, but this association was not seen in either the nr-axSpA
or MBP groups.
Patients on TNFi demonstrated lower MIP1β (mean 506.8 pg/ml vs 625.0 pg/ml, P = 0.001), and reported lower
fatigue (mean BASDAI Q1 score 3.7 vs 5.2, P < 0.001).
This work has identified an association between fatigue and serum biomarkers MIP1β and VEGF in AS patients,
while those on anti-TNF treatment were found to have both lower fatigue and MIP1β. The larger AS sample size and
relative low proportion of patients on TNFi must be appreciated, and hence these results require further validation in
another cohort. MIP1-α has previously been shown to decline with TNF inhibition in AS [6], with no similar previous
findings for MIP1β. A previous study, however, has linked MIP1β to fatigue in SLE [7], but this is the first work of
its type to raise a possible role in SpA.
Rheumatology key messages
• Fatigued AS patients demonstrate higher MIP1β and VEGF, but patients on TNFi have lower
MIP1β.
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